Bone-borne Palatal Expander With Corticotomy for Cleft Palate Patients

Intervention:

Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae for previously treated cleft palate patients.

• Preoperative Preparations: All data of the patient will be gathered including personal data, medical history, family history, and classification of palatal cleft will be registered;
• Laboratory investigations will be conducted (CBC, coagulation profile, weight). -Models from dental impressions are made to make standardized measurements which include:-
• IMD: distance between two lingual grooves of two opposing first molars
• ICD: distance between cusp tip if two opposing canines
• Alveolar cleft width
• Total palatal area
• The correct distractor module can be measured bone to bone with the fitting models to choose the distractor length.
• General operative procedures
• The procedures will be performed under general anesthesia with nasotracheal intubation.
• Local anaesthesia with vasoconstriction Epinephrine 1:100:000 will be injected in the palatal mucosa and mucolabial fold.
• The palatal incision is done between the premolar and molar or between the premolars.
• Maxillary vestibular incision followed by lateral corticotomy.
• Placement of distractor plates horizontally and fixing it with self-drilling screws between two roots on each side.
• Postoperative care:
• Cephalosporin antibiotic (Ceclor 125mg q12h) for 5 days.
• Otrivin nasal drops for 5 days.
• Pyrol drops Analgesic-Antipyretic Paracetamol (Acetaminophen )
• Patient will be followed up for 10 weeks.
• Activation of distractor is started after 1 week of surgery using the patient's key twice daily.
• Sample size Based on the previous paper by Carpenter et al. 2014, the expected difference in maximum expansion will be 7.3+/-5.4m. The investigators will need to study 6 patients to be able to reject the null hypothesis that this response difference is zero with probability (power) o.8. The type I error probability associated with this test of this null hypothesis is 0.05. This sample size is to be increased to 8 to compensate for possible losses during follow up. Sample size was calculated using PS: Power and Sample Size software version 3.1.2 (Vanderbilt University, Nashville, Tennessee, USA.)
• Recruitment Strategy
• Patients will be selected from outpatient clinic of Department of Oral and Maxillofacial surgery - Cairo University.
• Screening of patients will continue until the target population is achieved.
• Identifying and recruiting potential subjects is achieved through patient database.

1. Data collection, management, and analysis

• Data collection methods

1. Plans for assessment and collection of outcome
2. Amount of bone expansion will be measured by collecting linear measurements from CBCT and dental models.
3. Patient satisfaction will be measured using patient chart.
4. Plans to promote participant retention and complete follow-up
5. Telephone numbers of all patients included the study will be recorded as a part of the written consent.
6. All patients will be given a phone call at the time of the predetermined follow-up dates.

• Data management All data will be entered electronically. Patients' files are to be stored in numerical order and stored in secure and accessible place. All data will be maintained in storage for 1 year after completion of the study.
• Statistical methods Data will be analyzed using IBM SPSS advanced statistics (statistical Package for Social Sciences), version 21 (SPSS Inc., Chicago, IL). Numerical data will be described as mean and standard deviation or median and range. Categorical data will be described as numbers and percentages. Data will be explored for normality using Kolmogrov-Smirnov test and Shapiro-Wilk test. Comparisons between before and after treatment for normality distributed numeric variables will be done using the paired t-test while for non- normally distributed numeric variables will be done by Wilcoxon sign test. A p-value less than or equal to 0.05 will be considered statistically significant.

1. Outcome: A suitable statistical test will be used to evaluate palatal expansion.
2. Methods for any additional analysis:

No additional subgroup analysis.

1. Monitoring

• Data monitoring Data monitoring committee is independent from the supplying company of the palatal expander.
• Harms Patient will be closely monitored throughout the post operative period and any notices adverse effects will be managed as seen appropriate
• Auditing:

Auditing of the study design will be done by the research committee of the Department of Oral and Maxillofacial Surgery, Faculty of Oral and Dental Medicine, Cairo University.